ATM |
Ataxia telangiectasia mutated |
alt-NHEJ |
Alternative non-homologous end joining |
B-NHEJ |
Backup nonhomologous end-joining |
BER |
Base excision repair |
51BP1 |
P51 binging protein 1 |
c-NHEJ |
Canonical non-homologous end joining |
CtIP |
BRCA1 C-terminal Interacting Protein |
D-NHEJ |
DNA-PK-mediated nonhomologous end-joining |
DDR |
DNA damage response |
DSB |
DNA double strand break |
ESCC |
Esophageal squamous cell carcinoma |
FDA |
Food and drug administration |
HR |
Homologous recombination |
MMEJ |
Microhomology-mediated end-joining |
NHEJ |
Nonhomologous end-joining |
PARPi |
Poly (ADP-ribose) polymerase 1 inhibitor |
Polθ |
Polymerase theta |
Polθi |
Polymerase theta inhibitor |
ROS |
Reactive oxygen species |
RBBP8 |
Retinoblastoma binding protein 8 |
RPA |
Replication protein A |
RIF1 |
Replication timing regulatory factor 1 |
SSA |
Single strand annealing |
SSB |
Single strand break |
ssDNA |
Single stranded DNA |
SL |
Synthetic lethality |
XPF |
Xeroderma pigmentosum complementation group F |